Author + information
- Received January 12, 2011
- Revision received April 25, 2011
- Accepted May 10, 2011
- Published online October 11, 2011.
- Ki Hong Lee, MD⁎,
- Myung Ho Jeong, MD, PhD⁎,⁎ (, )
- Ha Mi Kim, RN⁎,
- Youngkeun Ahn, MD, PhD⁎,
- Jong Hyun Kim, MD†,
- Shung Chull Chae, MD, PhD‡,
- Young Jo Kim, MD, PhD§,
- Seung Ho Hur, MD, PhD∥,
- In Whan Seong, MD, PhD¶,
- Taek Jong Hong, MD, PhD#,
- Dong Hoon Choi, MD, PhD⁎⁎,
- Myeong Chan Cho, MD, PhD††,
- Chong Jin Kim, MD, PhD‡‡,
- Ki Bae Seung, MD, PhD§§,
- Wook Sung Chung, MD, PhD§§,
- Yang Soo Jang, MD, PhD∥∥,
- Seung Woon Rha, MD, PhD¶¶,
- Jang Ho Bae, MD, PhD##,
- Jeong Gwan Cho, MD, PhD⁎,
- Seung Jung Park, MD, PhD⁎⁎⁎,
- KAMIR (Korea Acute Myocardial Infarction Registry) Investigators
- ↵⁎Reprint requests and correspondence:
Dr. Myung Ho Jeong, Principal Investigator of Korea Acute Myocardial Infarction Registry, Heart Research Center, Chonnam National University Hospital, 671 Jaebongro, Dong-gu, Gwangju 501-757, South Korea
Objectives We investigated whether statin therapy could be beneficial in patients with acute myocardial infarction (AMI) who have baseline low-density lipoprotein cholesterol (LDL-C) levels below 70 mg/dl.
Background Intensive lipid-lowering therapy with a target LDL-C value <70 mg/dl is recommended in patients with very high cardiovascular risk. However, whether to use statin therapy in patients with baseline LDL-C levels below 70 mg/dl is controversial.
Methods We analyzed 1,054 patients with AMI who had baseline LDL-C levels below 70 mg/dl and survived at discharge from the Korean Acute MI Registry between November 2005 and December 2007. They were divided into 2 groups according to the prescribing of statins at discharge (statin group n = 607; nonstatin group n = 447). The primary endpoint was the composite of 1-year major adverse cardiac events, including death, recurrent MI, target vessel revascularization, and coronary artery bypass grafting.
Results Statin therapy significantly reduced the risk of the composite primary endpoint (adjusted hazard ratio [HR]: 0.56; 95% confidence interval [CI]: 0.34 to 0.89; p = 0.015). Statin therapy reduced the risk of cardiac death (HR: 0.47; 95% CI: 0.23 to 0.93; p = 0.031) and coronary revascularization (HR: 0.45, 95% CI: 0.24 to 0.85; p = 0.013). However, there were no differences in the risk of the composite of all-cause death, recurrent MI, and repeated percutaneous coronary intervention rate.
Conclusions Statin therapy in patients with AMI with LDL-C levels below 70 mg/dl was associated with improved clinical outcome.
This study was supported by a grant of the Korea Healthcare technology R&D project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (A084869). Dr. Chae has received research grants from GlaxoSmithKline, MSD, Novartis, Pfizer, and Sanofi-Aventis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received January 12, 2011.
- Revision received April 25, 2011.
- Accepted May 10, 2011.
- American College of Cardiology Foundation